UCP1172 

UCP1172 is an antibacterial (Antibacterial) agent and Dihydrofolate reductase inhibitor, with an IC₅₀ of 0.0089 μM against Staphylococcus aureus DfrB, 0.22 μM against DfrG, 0.41 μM against DfrA, and 0.030 μM against DfrK. UCP1172 potently inhibits the growth of MRSA/MSSA isolates carrying dfrG and dfrK (MIC values of 0.3125-0.625 μg/mL), shows weak activity against MRSA carrying dfrA (MIC of 5 μg/mL), and exerts extremely potent inhibitory effects on wild-type S. aureus ATCC 43300 (MIC of 0.0098 μg/mL). UCP1172 can be used in studies related to tuberculosis and Staphylococcus aureus infections^[1][2].

UCP1172 (0.0098-5 μg/mL; 18 hr) potently inhibits the growth of dfrG- and dfrK-harboring MRSA/MSSA clinical isolates (MIC values 0.3125-0.625 μg/mL), shows weaker activity against dfrA-harboring MRSA (MIC 5 μg/mL), and highly potently inhibits wild-type S. aureus ATCC 43300 (MIC 0.0098 μg/mL)^[2].
UCP1172 (0.0089-0.41 μM) potently inhibits wild-type S. aureus DfrB (IC₅₀ 0.0089 μM) and TMP-resistant DfrG (IC₅₀ 0.22 μM), DfrA (IC₅₀ 0.41 μM), and DfrK (IC₅₀ 0.030 μM) DHFR enzymes, with drastically improved potency over TMP for the resistant variants^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

416.47

C₂₄H₂₄N₄O₃

1922152-04-2

CCC1=NC(N)=NC(N)=C1C#C[C@@H](C2=CC(OC)=CC(C3=CC=C(C=C3)C(O)=O)=C2)C

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Ramharack P, et al. Dual-Target Mycobacterium tuberculosis Inhibition: Insights into the Molecular Mechanism of Antifolate Drugs. Int J Mol Sci. 2023 Sep 13;24(18):14021.

  [2]. Reeve SM, et al. MRSA Isolates from United States Hospitals Carry dfrG and dfrK Resistance Genes and Succumb to Propargyl-Linked Antifolates. Cell Chem Biol. 2016;23(12):1458-1467.